BRIEF published on 03/10/2026 at 09:05, 7 months 18 days ago GenSight Biologics lève 1,7 million d'euros lors d'une nouvelle levée de fonds. Stratégie Financière Essais Cliniques Thérapie Génique Collecte De Fonds Actions Et Bons De Souscription
BRIEF published on 03/10/2026 at 09:05, 7 months 18 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 7 months 18 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics réalise une levée de fonds de près de 1,7 million d'euros pour développer des thérapies géniques innovantes. Annonce de succès pour l'opération Biopharmaceutique Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
PRESS RELEASE published on 03/10/2026 at 09:00, 7 months 18 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 7 months 19 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
BRIEF published on 03/09/2026 at 07:35, 7 months 19 days ago GenSight Biologics : Point sur les Programmes d'Accès Précoce et l'Étude REVISE Thérapie Génique GenSight Biologics Neuropathie Optique Étude REVISE Accès Précoce
BRIEF published on 03/09/2026 at 07:35, 7 months 19 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 7 months 19 days ago GenSight Biologics fait le point sur ses programmes d'accès précoce et l'étude REVISE GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ® Étude REVISER Programmes D'accès Anticipé
PRESS RELEASE published on 03/09/2026 at 07:30, 7 months 19 days ago Informations privilégiées / Autres communiqués GenSight Biologics fait le point sur les programmes d'accès précoce de GS010/LUMEVOQ et sur l'étude REVISE en cours, avec des approbations en France, Israël et aux États-Unis Thérapie Génique GenSight Biologics GS010/LUMEVOQ Accès Précoce Dose REVISE
PRESS RELEASE published on 03/09/2026 at 07:30, 7 months 19 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
Published on 10/28/2026 at 22:35, 5 hours 48 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 15 hours 53 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 15 hours 53 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 15 hours 53 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 15 hours 53 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/29/2026 at 00:15, 4 hours 8 minutes ago Infinite Electronics Showcases Engineered Connectivity Solutions at electronica 2026
Published on 10/28/2026 at 21:35, 6 hours 48 minutes ago Food & Beverage Manufacturers Race to Scale AI Beyond the Pilot Stage
Published on 10/28/2026 at 21:15, 7 hours 8 minutes ago Amrize Completes $1 Billion Share Repurchase Program
Published on 10/28/2026 at 20:36, 7 hours 46 minutes ago Vonovia’s Core Business Remains Resilient as Higher Financing Costs and Weaker Transaction Business Shape 2027 Guidance and 2028 Objectives
Published on 10/28/2026 at 17:56, 10 hours 27 minutes ago OPR - Mise à disposition de l'addendum au rapport d'expertise indépendante
Published on 10/28/2026 at 17:45, 10 hours 38 minutes ago VOGO obtains FIBA (International Basketball Federation) Approval for its Instant Replay System.
Published on 10/28/2026 at 17:45, 10 hours 38 minutes ago Successful issue of a € 6.0 billion bond as part of the financing of the PTC acquisition
